Description: Pardes Biosciences is a clinical-stage biopharmaceutical company created by and for this moment to help solve pandemic-sized problems, starting with COVID-19. We are applying modern reversible-covalent chemistry as a starting point to discover and develop novel oral drug candidates while reimagining the patient journey to access these medicines. The company’s lead product candidate, PBI-0451, is being developed as a direct-acting, oral antiviral drug to treat and prevent SARS-CoV-2 infections, the virus responsible for COVID-19. Pardes Biosciences is on a mission to stop a pandemic and start a movement so patients everywhere can get well sooner.
Home Page: www.pardesbio.com
PRDS Technical Analysis
2173 Salk Avenue
Carlsbad,
CA
92008
United States
Phone:
415 649 8758
Officers
| Name | Title |
|---|---|
| Dr. Uri A. Lopatin M.D. | Founder & Director |
| Ms. Heidi Henson CPA | Chief Financial Officer |
| Mr. Thomas G. Wiggans | CEO & Chairman |
| Mr. Patrick O'Brien | Sr. VP of Investor Relations |
| Ms. Elizabeth Haber Lacy J.D. | Gen. Counsel & Corp. Sec. |
| Mr. Dave Kuo | Sr. VP of HR |
| Mr. Brian P. Kearney Pharm.D. | Chief Devel. Officer |
| Mr. Sean P. Brusky | Chief Commercial Officer |
| Valdas Jurkauskas Ph.D. | Sr. VP of Technical Operations |
| Ms. Ann D. Kwong Ph.D. | Exec. VP of Research |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.3702 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2021-12-27 |
| Fiscal Year End: | December |
| Full Time Employees: | 63 |